Actively Recruiting

Phase Not Applicable
All Genders
ID07378683

Machine Learning Model-Based Risk Stratification to Reduce Surgical Site Infection After Central Nervous System Tumor Surgery A Prospective, Single-Center Clinical Validation Study

Led by Ming Yang · Updated on 2026-01-30

500

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating a machine learning-based approach to reduce surgical site infections (SSI) in patients undergoing brain or spinal tumor surgery. This study aims to validate whether using an intelligent prediction model to identify high-risk patients and applying tailored preventive measures can lower infection rates. It also assesses safety, hospital stay length, medical costs, and the model's practical feasibility. The study is a prospective, single-center clinical validation conducted at the Chinese Academy of Medical Sciences Cancer Hospital.

CONDITIONS

Brief Title

A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a confirmed primary or metastatic brain or spinal tumor
  • Scheduled for elective craniotomy or spinal tumor surgery
  • Age 18 years or older
  • Expected survival longer than 3 months and able to comply with follow-up
  • Voluntary participation with written informed consent
Not Eligible

You will not qualify if you...

  • Active systemic or local infection before surgery
  • Use of therapeutic antibiotics within 72 hours prior to surgery
  • Severe immunosuppressive conditions or chronic high-dose immunosuppressant use
  • Pregnancy or breastfeeding
  • Known allergy or contraindication to antibiotics planned for the study
  • Any condition that may affect participation or outcome as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery

Duration - Day of surgery

Participants undergo elective craniotomy or spinal tumor surgery as part of their treatment.

1 visit (in-person)

Postoperative Care

Duration - Up to 90 days post-surgery

Participants receive postoperative care based on their risk of surgical site infection determined by a machine learning model. High-risk participants receive an enhanced, individualized intervention package including escalated antibiotic prophylaxis, intensified nutritional support, and enhanced monitoring. Low-risk participants receive standard postoperative care following established clinical pathways.

Follow-up visits as per standard clinical pathways within 90 days

Trial Site Locations

Total: 1 location

1

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, PUMC, China, 10010

Actively Recruiting

Loading map...

Research Team

M

Ming Yang, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Similar Trials

Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/...

Refractory Cancer

Actively Recruiting

2 locations

A Feasibility Study to Determine if a Novel Patient-derived ...

Central Nervous System Tumor

Actively Recruiting

1 location

Integrated Cancer Repository for Cancer Research

Pancreatic Cancer

Actively Recruiting

42 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here